Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia - Impact on enzyme activity and response to cytotoxics

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1851, Issue 7, 2015, Pages 919-928

  Morad, Samy A F ^a,e   Tan, Su Fern ^b   Feith, David J ^b,c   Kester, Mark ^c   Claxton, David F ^d   Loughran, Thomas P ^b,c   Barth, Brian M ^d   Fox, Todd E ^b   Cabot, Myles C ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d PENN STATE CANCER INSTITUTE   (United States)

^e South Valley University   (Egypt)

Author keywords

Ceramide; Leukemia; Sphingolipid metabolism; Tamoxifen; Triphenylethylenes

Indexed keywords

ACID CERAMIDASE; CASPASE 3; CERAMIDE; CYTOTOXIC AGENT; GLUCOSYLCERAMIDE; N (4 CARBOXYPHENYL)RETINAMIDE; N (4 HYDROXPHENYL)RETINAMIDE; NORTAMOXIFEN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; TAMOXIFEN; UNCLASSIFIED DRUG; VINCRISTINE; ANTIESTROGEN; CYTOTOXIN; N-DESMETHYLTAMOXIFEN; PHOSPHOTRANSFERASE; SPHINGOLIPID; SPHINGOSINE KINASE; STILBENE DERIVATIVE; TRIPHENYLETHYLENE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GLYCOSYLATION; HUMAN; HUMAN CELL; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHINGOLIPID METABOLISM; TREATMENT RESPONSE; ACUTE MYELOBLASTIC LEUKEMIA; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HL 60 CELL LINE; LIPID METABOLISM; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

CYTOTOXINS; ENZYME ACTIVATION; ESTROGEN ANTAGONISTS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIPID METABOLISM; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SPHINGOLIPIDS; STILBENES; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 84925781298     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2015.03.001     Document Type: Article

References (57)

1. D. Canals, and Y.A. Hannun Novel chemotherapeutic drugs in sphingolipid cancer research Handb. Exp. Pharmacol. 2013 211 238
2. S.A. Morad, and M.C. Cabot Ceramide-orchestrated signalling in cancer cells Nat. Rev. Cancer 13 2013 51 65
3. R. Savic, and E.H. Schuchman Use of acid sphingomyelinase for cancer therapy Adv. Cancer Res. 117 2013 91 115
4. M.-T. Dimanche-Boitrel, and A. Rebillard Sphingolipids and response to chemotherapy 2013 Springer
5. Y. Lavie, H. Cao, S.L. Bursten, A.E. Giuliano, and M.C. Cabot Accumulation of glucosylceramides in multidrug-resistant cancer cells J. Biol. Chem. 271 1996 19530 19536
6. G. Musumarra, V. Barresi, D.F. Condorelli, and S. Scire A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics Biol. Chem. 384 2003 321 327
7. Y.H. Zeidan, R.W. Jenkins, J.B. Korman, X. Liu, L.M. Obeid, J.S. Norris, and Y.A. Hannun Molecular targeting of acid ceramidase: implications to cancer therapy Curr. Drug Targets 9 2008 653 661
8. K.A. Orr Gandy, and L.M. Obeid Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors Biochim. Biophys. Acta 1831 2013 157 166
9. A. Senchenkov, D.A. Litvak, and M.C. Cabot Targeting ceramide metabolism - a strategy for overcoming drug resistance J. Natl. Cancer Inst. 93 2001 347 357
10. J.P. Truman, M. Garcia-Barros, L.M. Obeid, and Y.A. Hannun Evolving concepts in cancer therapy through targeting sphingolipid metabolism Biochim. Biophys. Acta 1841 2014 1174 1188
11. M.C. Cabot, A.E. Giuliano, A. Volner, and T.Y. Han Tamoxifen retards glycosphingolipid metabolism in human cancer cells FEBS Lett. 394 1996 129 131
12. Y. Lavie, H. Cao, A. Volner, A. Lucci, T.Y. Han, V. Geffen, A.E. Giuliano, and M.C. Cabot Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells J. Biol. Chem. 272 1997 1682 1687
13. J.V. Chapman, V. Gouaze-Andersson, and M.C. Cabot Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity Int. J. Oncol. 37 2010 1591 1597
14. S.A. Morad, J.C. Levin, S.F. Tan, T.E. Fox, D.J. Feith, and M.C. Cabot Novel off-target effect of tamoxifen - inhibition of acid ceramidase activity in cancer cells Biochim. Biophys. Acta 1831 2013 1657 1664
15. V. Gouaze-Andersson, and M.C. Cabot Sphingolipid metabolism and drug resistance in hematological malignancies Anticancer Agents Med. Chem. 11 2011 891 903
16. D. Mahadevan Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies? Leuk. Res. 30 2006 1077 1078
17. P. Borst, N. Zelcer, and A. van Helvoort ABC transporters in lipid transport Biochim. Biophys. Acta 1486 2000 128 144
18. C. Bedia, J. Casas, V. Garcia, T. Levade, and G. Fabrias Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases Chembiochem 8 2007 642 648
19. J.V. Chapman, V. Gouaze-Andersson, M.C. Messner, M. Flowers, R. Karimi, M. Kester, B.M. Barth, X. Liu, Y.Y. Liu, A.E. Giuliano, and M.C. Cabot Metabolism of short-chain ceramide by human cancer cells - implications for therapeutic approaches Biochem. Pharmacol. 80 2010 308 315
20. S.A. Morad, J.C. Levin, S.S. Shanmugavelandy, M. Kester, G. Fabrias, C. Bedia, and M.C. Cabot Ceramide-antiestrogen nanoliposomal combinations - novel impact of hormonal therapy in hormone-insensitive breast cancer Mol. Cancer Ther. 11 2012 2352 2361
21. T.E. Fox, M.C. Bewley, K.A. Unrath, M.M. Pedersen, R.E. Anderson, D.Y. Jung, L.S. Jefferson, J.K. Kim, S.K. Bronson, J.M. Flanagan, and M. Kester Circulating sphingolipid biomarkers in models of type 1 diabetes J. Lipid Res. 52 2011 509 517
22. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
23. D.H. Holman, L.S. Turner, A. El-Zawahry, S. Elojeimy, X. Liu, J. Bielawski, Z.M. Szulc, K. Norris, Y.H. Zeidan, Y.A. Hannun, A. Bielawska, and J.S. Norris Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells Cancer Chemother. Pharmacol. 61 2008 231 242
24. B.J. Maurer, M.H. Kang, J.G. Villablanca, J. Janeba, S. Groshen, K.K. Matthay, P.M. Sondel, J.M. Maris, H.A. Jackson, F. Goodarzian, H. Shimada, S. Czarnecki, B. Hasenauer, C.P. Reynolds, and A. Marachelian Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium Pediatr. Blood Cancer 60 2013 1801 1808
25. A. Abe, D. Wu, J.A. Shayman, and N.S. Radin Metabolic effects of short-chain ceramide and glucosylceramide on sphingolipids and protein kinase C Eur. J. Biochem. 210 1992 765 773
26. B.S. Zolnik, S.T. Stern, J.M. Kaiser, Y. Heakal, J.D. Clogston, M. Kester, and S.E. McNeil Rapid distribution of liposomal short-chain ceramide in vitro and in vivo Drug Metab. Dispos. 36 2008 1709 1715
27. B.J. Maurer, L.S. Metelitsa, R.C. Seeger, M.C. Cabot, and C.P. Reynolds Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines J. Natl. Cancer Inst. 91 1999 1138 1146
28. M.C. Cabot, T.Y. Han, and A.E. Giuliano The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation FEBS Lett. 431 1998 185 188
29. S.A. Morad, M.C. Messner, J.C. Levin, N. Abdelmageed, H. Park, A.H. Merrill Jr., and M.C. Cabot Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells Cancer Chemother. Pharmacol. 71 2013 635 645
30. D.K. Perry, J. Carton, A.K. Shah, F. Meredith, D.J. Uhlinger, and Y.A. Hannun Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis J. Biol. Chem. 275 2000 9078 9084
31. L. Lee, A. Abe, and J.A. Shayman Improved inhibitors of glucosylceramide synthase J. Biol. Chem. 274 1999 14662 14669
32. H. Sietsma, R.J. Veldman, D. Kolk, B. Ausema, W. Nijhof, W. Kamps, E. Vellenga, and J.W. Kok 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine Clin. Cancer Res. 6 2000 942 948
33. R.S. Olshefski, and S. Ladisch Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity Int. J. Cancer 93 2001 131 138
34. S.J. Furlong, N.D. Ridgway, and D.W. Hoskin Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin Int. J. Oncol. 32 2008 537 544
35. R.J. Watters, T.E. Fox, S.F. Tan, S. Shanmugavelandy, J.E. Choby, K. Broeg, J. Liao, M. Kester, M.C. Cabot, T.P. Loughran, and X. Liu Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia Leuk. Lymphoma 54 2013 1288 1296
36. E. Norris-Cervetto, R. Callaghan, F.M. Platt, R.A. Dwek, and T.D. Butters Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells J. Biol. Chem. 279 2004 40412 40418
37. L. Chai, R.P. McLaren, A. Byrne, W.L. Chuang, Y. Huang, M.R. Dufault, J. Pacheco, S. Madhiwalla, X. Zhang, M. Zhang, B.A. Teicher, K. Carter, S.H. Cheng, J.P. Leonard, Y. Xiang, M. Vasconcelles, M.A. Goldberg, D.P. Copeland, K.W. Klinger, J. Lillie, S.L. Madden, and Y.A. Jiang The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function Int. J. Oncol. 38 2011 701 711
38. J.V. Chapman, V. Gouaze-Andersson, R. Karimi, M.C. Messner, and M.C. Cabot P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells Exp. Cell Res. 317 2011 1736 1745
39. L. Camacho, O. Meca-Cortes, J.L. Abad, S. Garcia, N. Rubio, A. Diaz, T. Celia-Terrassa, F. Cingolani, R. Bermudo, P.L. Fernandez, J. Blanco, A. Delgado, J. Casas, G. Fabrias, and T.M. Thomson Acid ceramidase as a therapeutic target in metastatic prostate cancer J. Lipid Res. 54 2013 1207 1220
40. T.H. Beckham, J.C. Cheng, P. Lu, S.T. Marrison, J.S. Norris, and X. Liu Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling PLoS One 8 2013 e76593
41. C. Bedia, J. Casas, N. Andrieu-Abadie, G. Fabrias, and T. Levade Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine J. Biol. Chem. 286 2011 28200 28209
42. M.V. Shah, R. Zhang, R. Irby, R. Kothapalli, X. Liu, T. Arrington, B. Frank, N.H. Lee, and T.P. Loughran Jr. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes Blood 112 2008 770 781
43. V. Gouaze-Andersson, M. Flowers, R. Karimi, G. Fabrias, A. Delgado, J. Casas, and M.C. Cabot Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide Prostate 71 2011 1064 1073
44. M.C. Morales, G. Perez-Yarza, N.N. Rementeria, M.D. Boyano, A. Apraiz, A. Gomez-Munoz, E. Perez-Andres, and A. Asumendi 4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated downstream by Bcl-2 Free Radic. Res. 41 2007 591 601
45. B.J. Maurer, L. Melton, C. Billups, M.C. Cabot, and C.P. Reynolds Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism J. Natl. Cancer Inst. 92 2000 1897 1909
46. M. Pallis, and N. Russell Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia Leukemia 18 2004 1927 1930
47. S. Batra, C.P. Reynolds, and B.J. Maurer Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators Cancer Res. 64 2004 5415 5424
48. H. Devalapally, Z. Duan, M.V. Seiden, and M.M. Amiji Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles Clin. Cancer Res. 14 2008 3193 3203
49. Y. Jiang, N.A. DiVittore, J.M. Kaiser, S.S. Shanmugavelandy, J.L. Fritz, Y. Heakal, H.R. Tagaram, H. Cheng, M.C. Cabot, K.F. Staveley-O'Carroll, M.A. Tran, T.E. Fox, B.M. Barth, and M. Kester Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer Cancer Biol. Ther. 12 2011 574 585
50. S.J. O'Day, P.D. Boasberg, T.S. Kristedja, M. Martin, H.J. Wang, P. Fournier, M. Cabot, M.W. DeGregorio, and G. Gammon High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma Cancer 92 2001 609 619
51. M.W. Holliday Jr., S.B. Cox, M.H. Kang, and B.J. Maurer C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines PLoS One 8 2013 e74768
52. F. Scarlatti, C. Bauvy, A. Ventruti, G. Sala, F. Cluzeaud, A. Vandewalle, R. Ghidoni, and P. Codogno Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1 J. Biol. Chem. 279 2004 18384 18391
53. S. Pattingre, C. Bauvy, S. Carpentier, T. Levade, B. Levine, and P. Codogno Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy J. Biol. Chem. 284 2009 2719 2728
54. P. de Medina, B.L. Payre, J. Bernad, I. Bosser, B. Pipy, S. Silvente-Poirot, G. Favre, J.C. Faye, and M. Poirot Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells J. Pharmacol. Exp. Ther. 308 2004 1165 1173
55. E. Bonhoure, D. Pchejetski, N. Aouali, H. Morjani, T. Levade, T. Kohama, and O. Cuvillier Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1 Leukemia 20 2006 95 102
56. B.M. Barth, M.C. Cabot, and M. Kester Ceramide-based therapeutics for the treatment of cancer Anticancer Agents Med. Chem. 11 2011 911 919
57. E. Berman, M. McBride, and W. Tong Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines Leukemia 8 1994 1191 1196